MIX23 and neoplasm: Therefore, we suggested that CCDC58 might affect the sensitivity of cancer patients to immunotherapy by interfering with the tumor immune microenvironment, and it might be a potential therapeutic target and a new biomarker for predicting the prognosis of patients.